Evidence map›Paper›PMID 11437411›Full record

ArticleBritish journal of cancer2001

High density oligonucleotide array analysis of interferon- alpha2a sensitivity and transcriptional response in melanoma cells.

U Certa, M Seiler, E Padovan, G C Spagnoli

Open access · hybridAbstract read
In one paragraph

Article in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Emerging roles of FAM14 family members (G1P3/ISG 6-16 and ISG12/IFI27) in innate immunity and cancer.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2011
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

U CertaRoche Genetics, F. Hoffmann-La Roche Ltd., Bau 93/610, Basel, 4070, Switzerland.
M Seiler
E Padovan
G C Spagnoli
Roche (Switzerland) · CHUniversity of Basel · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interferon alpha (IFN-alpha) represents an adjuvant therapy of proven effectiveness in increasing disease-free interval and survival in subgroups of melanoma patients. Since high doses of cytokine are required, the treatment is often accompanied by toxic side effects. Furthermore, naturally occurring insensitivity to IFN-alpha may hamper its therapeutic efficacy. Clinical, molecular or immunological markers enabling the selection of potential responders have not been identified so far. To explore the molecular basis of IFN-alpha responsiveness, we analysed the expression pattern of about 7000 genes in IFN-alpha sensitive and resistant cell lines and we compared the transcription profiles of cells cultured in the presence or absence of the cytokine using high-density oligonucleotide arrays. Melanoma cell lines were screened for their sensitivity to proliferation inhibition and HLA class I induction upon IFN-alpha treatment by standard 3H-thymidine incorporation and flow-cytometry. The study of 4 sensitive and 2 resistant cell lines allowed the identification of 4 genes (RCC1, IFI16, hox2 and h19) preferentially transcribed in sensitive cells and 2 (SHB and PKC-zeta) preferentially expressed in resistant cells. IFN-alpha stimulation resulted in the expression of a panel of 19 known inducible genes in sensitive but not in resistant cells. Moreover a group of 30 novel IFN-alpha inducible genes was identified. These data may provide a useful basis to develop diagnostic tools to select potential IFN-alpha responders eligible for treatment, while avoiding unnecessary toxicity to non-responders. Furthermore, by extending the knowledge of the polymorphic effects of IFN-alpha on gene expression, they offer novel clues to the study of its pleiotropic toxicity.

Indexed as

Antigens, NeoplasmAntineoplastic AgentsCell DivisionDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticGenetic Markersgp100 Melanoma AntigenHistocompatibility Antigens Class IHLA AntigensHumansInterferon-alphaInterferon alpha-2MART-1 AntigenMelanomaMembrane GlycoproteinsMultigene FamilyAntigens, NeoplasmAntineoplastic AgentsGenetic Markersgp100 Melanoma AntigenHistocompatibility Antigens Class IHLA AntigensInterferon-alphaInterferon alpha-2MART-1 AntigenMembrane GlycoproteinsMLANA protein, humanNeoplasm ProteinsPMEL protein, humanProteinsRecombinant Proteins

Identifiers

PMID11437411
PMCPMC2363915
OpenAlexW1991432638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.